Key result
Intracerebroventricular administration of the ACE2 activator diminazene aceturate significantly reduced immobility time in mice (p<0.0001), an effect that was abolished by MAS receptor blockade.
Why the study?
The neuroprotective ACE2/Ang (1-7)/MAS receptor pathway is a potential therapeutic target for depression, prompting investigation into whether the ACE2 activator diminazene aceturate produces antidepressant-like effects.
Does intracerebroventricular administration of the ACE2 activator DIZE reduce depressive-like behavior in mice?
Does intracerebroventricular administration of the ACE2 activator DIZE reduce depressive-like behavior in mice?
Answers are grounded in this paper and cite their sources.
Central activation of ACE2 by diminazene aceturate produces antidepressant-like effects in mice via the Ang (1-7)/MAS receptor pathway.
Angiotensin (Ang)-converting-enzyme (ACE) 2 converts Ang II into Ang (1-7), which in turn acts on MAS receptors (ACE2/Ang (1-7)/MAS receptors pathway). This pathway has neuroprotective properties, making it a potential therapeutic target for psychiatric disorders such as depression. Thus, we examined the effects of diminazene aceturate (DIZE), an ACE2 activator, on depressive-like behavior using behavioral, pharmacological, and biochemical assays. To determine whether DIZE or Ang (1-7) produce antidepressant-like effects, we measured the duration of immobility of mice in the tail suspension test following their intracerebroventricular administration. Next, we measured the levels of ACE2 activation in the cerebral cortex, prefrontal cortex, hippocampus, and amygdala after DIZE injection, and examined which cell types, including neurons, microglia, and astrocytes, express ACE2 in the hippocampus using immunofluorescence. Administration of DIZE or Ang (1-7) significantly shortened the duration of immobility time in the tail suspension test, while this effect was inhibited by the co-administration of the MAS receptor antagonist A779. DIZE activated ACE2 in the hippocampus. ACE2 was localized to neurons, astrocytes, and microglia in the hippocampus. In conclusion, these results suggest that DIZE may act on ACE2-positive cells in the hippocampus where it increases the activity of ACE2, thereby enhancing signaling of the ACE2/Ang (1-7)/MAS receptor pathway and resulting in antidepressant-like effects.
No takes yet. Share an insight, caveat, or question.
Nakagawasai et al. (2023) studied Depressive-like behavior (n=345). Diminazene aceturate (DIZE) vs. Vehicle (Ringer's solution) was evaluated on Immobility time in the tail suspension test (p=<0.0001). Intracerebroventricular administration of the ACE2 activator diminazene aceturate significantly reduced immobility time in mice (p<0.0001), an effect that was abolished by MAS receptor blockade.
Synapse has enriched 10 related papers. Consider them for comparative context: